DDP-4 inhibitors versus sulphonylureas and cardiovascular outcomes: a meta-analysis of observational comparative studies

Abstract

INTRODUCTION: Dipeptidyl peptidase IV inhibitors (DPP4i) and sulphonylureas are commonly prescribed antidiabetic treatments, particularly after the failure of metformin monotherapy. Although DPP4i have demonstrated non-inferiority versus to placebo in clinical trials, their relative effectiveness in reducing cardiovascular events compared to sulphonylureas was evaluated in observational studies.

AIMS: To evaluate the risk of mortality (all-cause and cardiovascular) and major cardiovascular adverse events (MACE) in patients treated with DPP4i versus sulphonylureas.

Read More

Citation
ATTD 2019 Poster.